NSA Digital Archive/iStock via Getty Images
- Marinus Pharmaceuticals (NASDAQ:MRNS) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older.
- CDD is a genetic disorder caused due to mutations in the CDKL5 gene. It is characterized by seizures, developmental delay and intellectual disability.
- Ztalmy, which is an oral treatment, got U.S. FDA approval earlier this year in March.
- Marinus (MRNS) also said it had established a patient support program called Ztalmy One which facilitates access to the treatment, including prescription benefits and financial support for patients with no insurance.